2018
Role of NOD2 in antiphospholipid antibody-induced and bacterial MDP amplification of trophoblast inflammation
Mulla MJ, Pasternak MC, Salmon JE, Chamley LW, Abrahams VM. Role of NOD2 in antiphospholipid antibody-induced and bacterial MDP amplification of trophoblast inflammation. Journal Of Autoimmunity 2018, 98: 103-112. PMID: 30594350, DOI: 10.1016/j.jaut.2018.12.003.Peer-Reviewed Original ResearchConceptsMuramyl dipeptideAbsence of aPLAnti-angiogenic profileNovel danger signalPresence of aPLRole of NOD2IL-1β expressionMaternal-fetal interfaceActivation of NOD2IL-1β productionBacterial muramyl dipeptideAntiphospholipid antibodiesCommon bacterial componentsPregnancy complicationsPregnancy outcomesAdverse outcomesIL-1βTrophoblast responsesExtravillous trophoblastsHigh riskPreeclampsiaDanger signalsBacterial infectionsVEGF secretionInflammation
2017
Mechanisms of Antiphospholipid Antibody-Mediated Pregnancy Morbidity
Salmon J, Mineo C, Giles I, Chamley L, Meroni P, Abrahams V. Mechanisms of Antiphospholipid Antibody-Mediated Pregnancy Morbidity. 2017, 117-143. DOI: 10.1007/978-3-319-55442-6_6.Peer-Reviewed Original ResearchIntrauterine growth restrictionPregnancy complicationsAntiphospholipid syndromeAntiphospholipid antibodiesRecurrent early pregnancy lossImpaired placental functionLate obstetrical complicationsNon-thrombotic eventsPartial beneficial effectEarly pregnancy lossMaternal-fetal interfacePregnancy morbidityAPS patientsObstetrical complicationsThrombotic eventsTrophoblast functionsPregnancy lossGrowth restrictionPlacental functionHigh riskComplicationsPathogenic mechanismsComplement activationBeneficial effectsPatients
2012
What is the Mechanism(s) of Antiphospholipid Antibody-Mediated Pregnancy Morbidity?
Abrahams V, Borghi M, Meroni P, Rand J, Raschi E, Salmon J, Tedesco F, Tincani A. What is the Mechanism(s) of Antiphospholipid Antibody-Mediated Pregnancy Morbidity? 2012, 79-101. DOI: 10.1007/978-1-4614-3194-7_5.Peer-Reviewed Original ResearchPregnancy complicationsAntiphospholipid syndromeAntiphospholipid antibodiesRecurrent early pregnancy lossImpaired placental functionLate obstetrical complicationsNon-thrombotic eventsPartial beneficial effectIntrauterine growth restrictionEarly pregnancy lossMaternal-fetal interfacePregnancy morbidityAPS patientsObstetrical complicationsThrombotic eventsTrophoblast functionsPregnancy lossGrowth restrictionPlacental functionHigh riskComplicationsPathogenic mechanismsComplement activationBeneficial effectsPatients